# Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy

> **NCT02412462** · PHASE1 · COMPLETED · sponsor: **Alethia Biotherapeutics** · enrollment: 15 (actual)

## Conditions studied

- Solid Tumor
- Metastatic Cancer

## Interventions

- **DRUG:** AB-16B5

## Key facts

- **NCT ID:** NCT02412462
- **Lead sponsor:** Alethia Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2017-01
- **Final completion:** 2017-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02412462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02412462, "Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02412462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*